Cataract - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/05/15
頁 數：59頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Cataract - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Cataract - Pipeline Review, H1 2014’, provides an overview of the Cataract’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cataract
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cataract
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Cataract - Pipeline Review, H1 2014’, provides an overview of the Cataract’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cataract, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cataract
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Cataract and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Cataract products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cataract pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cataract
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cataract pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cataract Overview 6
Therapeutics Development 7
Pipeline Products for Cataract - Overview 7
Pipeline Products for Cataract - Comparative Analysis 8
Cataract - Therapeutics under Development by Companies 9
Cataract - Therapeutics under Investigation by Universities/Institutes 11
Cataract - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Cataract - Products under Development by Companies 14
Cataract - Products under Investigation by Universities/Institutes 15
Cataract - Companies Involved in Therapeutics Development 16
EyeGate Pharmaceuticals, Inc. 16
Laboratorios Sophia S.A. de C.V. 17
Laila Pharmaceuticals Pvt. Ltd. 18
CalAsia Pharmaceuticals, Inc. 19
Cataract - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
dexamethasone acetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PRO-155 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LP-01309 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MTP-131 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
caffeic acid phenethyl ester - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug For Cataract - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Various Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Cataract - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small molecules to Activate Alpha-Crystallin for Non-surgical Cataracts and Multiple Sclerosis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cataract - Recent Pipeline Updates 43
Cataract - Dormant Projects 48
Cataract - Discontinued Products 49
Cataract - Product Development Milestones 50
Featured News & Press Releases 50
Apr 30, 2013: Omeros Ophthalmology Product OMS302 Granted Eligibility For European Centralized Review 50
Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency 50
Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302 51
May 19, 2011: Omeros Advances OMS302 Into Phase III Clinical Development Program 52
Mar 23, 2011: Omeros's Ophthalmology Product OMS302 Achieves Co-Primary Endpoints In Phase IIb Clinical Study 52
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 53
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 54
Aug 23, 2010: InSite Vision Initiates Phase I/II Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling 55
Jul 27, 2010: Omeros Initiates Phase IIb Clinical Trial For OMS302 In Patients Undergoing Cataract Surgery 56
Jan 05, 2010: Icon Bioscience Initiates Phase II/III Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate IBI-10090 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Cataract, H1 2014 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2014 16
Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2014 17
Cataract - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 18
Cataract - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Cataract Therapeutics - Recent Pipeline Updates, H1 2014 43
Cataract - Dormant Projects, H1 2014 48
Cataract - Discontinued Products, H1 2014 49
List of Figures
Number of Products under Development for Cataract, H1 2014 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cataract Overview 6
Therapeutics Development 7
Pipeline Products for Cataract - Overview 7
Pipeline Products for Cataract - Comparative Analysis 8
Cataract - Therapeutics under Development by Companies 9
Cataract - Therapeutics under Investigation by Universities/Institutes 11
Cataract - Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Cataract - Products under Development by Companies 14
Cataract - Products under Investigation by Universities/Institutes 15
Cataract - Companies Involved in Therapeutics Development 16
EyeGate Pharmaceuticals, Inc. 16
Laboratorios Sophia S.A. de C.V. 17
Laila Pharmaceuticals Pvt. Ltd. 18
CalAsia Pharmaceuticals, Inc. 19
Cataract - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
dexamethasone acetate - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
PRO-155 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
LP-01309 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MTP-131 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
caffeic acid phenethyl ester - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Drug For Cataract - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Various Diseases - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug For Cataract - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small molecules to Activate Alpha-Crystallin for Non-surgical Cataracts and Multiple Sclerosis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Cataract - Recent Pipeline Updates 43
Cataract - Dormant Projects 48
Cataract - Discontinued Products 49
Cataract - Product Development Milestones 50
Featured News & Press Releases 50
Apr 30, 2013: Omeros Ophthalmology Product OMS302 Granted Eligibility For European Centralized Review 50
Nov 29, 2011: Omeros Submits Paediatric Investigation Plan Letter Of Intent For OMS302 To European Medicines Agency 50
Oct 11, 2011: Omeros Announces First Patients Treated In Phase III Clinical Program Evaluating OMS302 51
May 19, 2011: Omeros Advances OMS302 Into Phase III Clinical Development Program 52
Mar 23, 2011: Omeros's Ophthalmology Product OMS302 Achieves Co-Primary Endpoints In Phase IIb Clinical Study 52
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 53
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 54
Aug 23, 2010: InSite Vision Initiates Phase I/II Clinical Study Of ISV-303 For Post-Surgical Ocular Pain And Swelling 55
Jul 27, 2010: Omeros Initiates Phase IIb Clinical Trial For OMS302 In Patients Undergoing Cataract Surgery 56
Jan 05, 2010: Icon Bioscience Initiates Phase II/III Pivotal Clinical Study Of Novel Ophthalmic Drug Candidate IBI-10090 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 59
Disclaimer 59
List of Tables
Number of Products under Development for Cataract, H1 2014 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Products under Development by Companies, H1 2014 14
Products under Investigation by Universities/Institutes, H1 2014 15
Cataract - Pipeline by EyeGate Pharmaceuticals, Inc., H1 2014 16
Cataract - Pipeline by Laboratorios Sophia S.A. de C.V., H1 2014 17
Cataract - Pipeline by Laila Pharmaceuticals Pvt. Ltd., H1 2014 18
Cataract - Pipeline by CalAsia Pharmaceuticals, Inc., H1 2014 19
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Stage and Target, H1 2014 22
Number of Products by Stage and Mechanism of Action, H1 2014 24
Number of Products by Stage and Route of Administration, H1 2014 26
Number of Products by Stage and Molecule Type, H1 2014 28
Cataract Therapeutics - Recent Pipeline Updates, H1 2014 43
Cataract - Dormant Projects, H1 2014 48
Cataract - Discontinued Products, H1 2014 49
List of Figures
Number of Products under Development for Cataract, H1 2014 7
Number of Products under Development for Cataract - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 13
Assessment by Monotherapy Products, H1 2014 20
Number of Products by Top 10 Target, H1 2014 21
Number of Products by Stage and Top 10 Target, H1 2014 22
Number of Products by Top 10 Mechanism of Action, H1 2014 23
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 24
Number of Products by Top 10 Route of Administration, H1 2014 25
Number of Products by Stage and Top 10 Route of Administration, H1 2014 26
Number of Products by Top 10 Molecule Type, H1 2014 27
Number of Products by Stage and Top 10 Molecule Type, H1 2014 28
